Page 356 - AIDSBK23C
P. 356

Page 356




               720     Holly EA, Ralston ML, Darragh TM, Greenblatt RM, Jay N, Palefsky JM. Prevalence
                       and risk factors for anal squamous intraepithelial lesions in women. J Natl Cancer Inst.
                       2001;93:843-849.

               721     Cranston RD, Hart SD, Gornbein JA, Hirschowitz SL, Cortina G, Moe AA. The
                       prevalence, and predictive value, of abnormal anal cytology to diagnose anal dysplasia in
                       a population of HIV-positive men who have sex with men. Int J STD AIDS. 2007;18:77-
                       80.

               722     Rodgers S, Leslie KS. Skin infections in HIV-infected individuals in the era of HAART.
                       Curr Opin Infect Dis. 2011;24:124-129.

               723     Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal
                       opportunistic pathogens. Gastroenterology. 2009;136:1952-1965.

               724     Kotler DP. HIV infection and the gastrointestinal tract. AIDS. 2005;19:107-117.

               725     Mangili A, Murman DH, Zampini AM, Wanke CA. Nutrition and HIV infection: review
                       of weight loss and wasting in the era of highly active antiretroviral therapy from the
                       nutrition for healthy living cohort. Clin Infect Dis. 2006;42:836-842.

               726     Dworkin MS, Williamson JM; Adult/Adolescent Spectrum of HIV Disease Project. AIDS
                       wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir
                       Immune Defic Syndr.  2003;33:267-273.

               727     Shlay JC, Bartsch G, Penq G, Wang J, Grunfeld C, Gibert CL, Visnegarwala F, et al.
                       Long-term body composition and metabolic changes in antiretroviral naïve persons
                       randomized to protease inhibitor-, nonnucleoside reverse transcriptase inhibitor-, or
                       protease inhibitor plus nonnucleoside reverse transcriptase inhibitor-based strategy. J
                       Acquir Immune Defic Syndr. 2007;44:506-517.

               728     Mallewa JE, Wilkins E, Vilar J, Mallewa M, Doran D, Back D, Pirmohamed M. HIV-
                       associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J
                       Antimicrob Chemother. 2008;62:648-660.

               729     Sweeney LL, Brennan AM, Mantzoros CS. The role of adipokines in relation to HIV
                       lipodystrophy. AIDS. 2007;21:895-904..

               730     Guaraldi G, Orlando G, Squillace N, Roverato A, De Fazio D, Vandelli M, Nardini G,
                       Beghetto B, De Paola M, Esposito R, Palella F. Prevalence of and risk factors for pubic
                       lipoma development in HIV-infected persons. J. Acquir. Immune Defic. Syndr.
                       2007;45:72-76.
   351   352   353   354   355   356   357   358   359   360   361